Uploading C:\Program Files\Stnexp\Queries\10651496a.str



chain nodes :
11 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
ring/chain nodes :
27
chain bonds :
7-25 11-12 16-21 21-22 22-23 22-24 25-26 25-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
5-7 6-9 7-8 7-25 8-9 11-12 16-21 21-22 22-23 22-24 25-26 25-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

G1:O,S,N,SO2,NH,NH2

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS

L3 STRUCTURE UPLOADED

=> s l3 sub=l2 full
FULL SUBSET SEARCH INITIATED 19:58:27 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 178 TO ITERATE

100.0% PROCESSED 178 ITERATIONS 152 ANSWERS
SEARCH TIME: 00.00.01

L4 152 SEA SUB=L2 SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10651496b.str



chain nodes :
11 21 22 23 24 25 26 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
ring/chain nodes :
27
chain bonds :
7-25 11-12 16-21 21-22 22-23 22-24 25-26 25-27 27-28 27-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
5-7 6-9 7-8 7-25 8-9 11-12 16-21 21-22 22-23 22-24 25-26 25-27
exact bonds :
27-28 27-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

G1:O,S,N,SO2,NH,NH2

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l5 sub=l4 sub
'SUB=L4' IS NOT VALID HERE
For additional help, enter "HELP SEARCH".

=> s l5 sub=l4 full
FULL SUBSET SEARCH INITIATED 20:00:41 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 152 TO ITERATE

100.0% PROCESSED 152 ITERATIONS 68 ANSWERS
SEARCH TIME: 00.00.01

L6 68 SEA SUB=L4 SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 240.01 240.22

FILE 'CAPLUS' ENTERED AT 20:00:52 ON 11 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Dec 2005 VOL 143 ISS 25
FILE LAST UPDATED: 9 Dec 2005 (20051209/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 1 L6

=> d l7

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:203828 CAPLUS
DN 140:253450
TI Preparation of azaarene derivatives as neovascularization inhibitors
IN Tsuruoka, Akihiko; Matsushima, Tomohiro; Matsukura, Masayuki; Miyazaki, Kazuki; Takahashi, Keiko; Kamata, Junichi; Fukuda, Yoshio
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DT Patent

```
LA   Japanese
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
PI   WO 2004020434          A1    20040311    WO 2003-JP10964          20030828
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2488739             AA    20040311    CA 2003-2488739          20030828
     EP 1522540             A1    20050413    EP 2003-791389           20030828
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003013871          A     20050719    BR 2003-13871            20030828
     US 2005187236          A1    20050825    US 2003-651496           20030829
     NO 2005001577          A     20050527    NO 2005-1577             20050329
PRAI JP 2002-253123         A     20020830
     US 2003-464690P        P     20030422
     WO 2003-JP10964        W     20030828
OS   MARPAT 140:253450
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l4
L8            2 L4

=> d l8 1-2 ibib abs

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:203828  CAPLUS
DOCUMENT NUMBER:          140:253450
TITLE:                    Preparation of azaarene derivatives as
                          neovascularization inhibitors
INVENTOR(S):              Tsuruoka, Akihiko; Matsushima, Tomohiro; Matsukura,
                          Masayuki; Miyazaki, Kazuki; Takahashi, Keiko; Kamata,
                          Junichi; Fukuda, Yoshio
PATENT ASSIGNEE(S):       Eisai Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 347 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
     WO 2004020434          A1    20040311    WO 2003-JP10964          20030828
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
```

BF, BJ, CF, CG, CI, CM; GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2488739	AA	20040311	CA 2003-2488739		20030828
EP 1522540	A1	20050413	EP 2003-791389		20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013871	A	20050719	BR 2003-13871		20030828
US 2005187236	A1	20050825	US 2003-651496		20030829
NO 2005001577	A	20050527	NO 2005-1577		20050329
PRIORITY APPLN. INFO.:			JP 2002-253123	A	20020830
			US 2003-464690P	P	20030422
			WO 2003-JP10964	W	20030828

OTHER SOURCE(S): MARPAT 140:253450

GI



I

AB The title compds. I [X1 is nitrogen or a group represented by the general formula CR10 ; X2 is nitrogen or a group represented by the general formula CR11 ; Y is oxygen or the like; R1 is C1-6 alkoxy, optionally substituted C6-10 aryloxy, a group represented by the general formula NR12aR12b, or the like; R2 is hydrogen, optionally substituted C1-6 alkyl, or the like; R3 - R8, R10, and R11 are each independently hydrogen, halogeno, optionally substituted C1-6 alkyl, or the like; R9 is a group represented by the general formula NR16aR16b, or the like; and R12a, R12b, R16a, and R16b are each independently hydrogen, optionally substituted C1-6 alkyl, or the like] are prepared Compds. of this invention showed IC50 values of 3 nM to 40 nM against VEGFR2 kinase.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:314913 CAPLUS

DOCUMENT NUMBER: 136:340689

TITLE: Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis

INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 699 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
WO 2002032872	C1	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2426461	AA	20020425	CA 2001-2426461	20011019
AU 2001095986	A5	20020429	AU 2001-95986	20011019
EP 1415987	A1	20040506	EP 2001-976786	20011019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1506962	A2	20050216	EP 2004-25700	20011019
EP 1506962	A3	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 525324	A	20050324	NZ 2001-525324	20011019
JP 3712393	B2	20051102	JP 2002-536056	20011019
RU 2264389	C2	20051120	RU 2003-114740	20011019
NO 2003001731	A	20030619	NO 2003-1731	20030414
US 2004053908	A1	20040318	US 2003-420466	20030418
ZA 2003003567	A	20040810	ZA 2003-3567	20030508
JP 2005072474	A2	20051006	JP 2005-124034	20050421

PRIORITY APPLN. INFO.:

JP 2000-320420	A	20001020
JP 2000-386195	A	20001220
JP 2001-46685	A	20010222
EP 2001-976786	A3	20011019
JP 2002-536056	A3	20011019
WO 2001-JP9221	W	20011019

OTHER SOURCE(S): MARPAT 136:340689
GI

Q= 

AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1,2,3), etc.; and Tg1 = a group of the

general formula -Eg-CO-NRg1(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rg1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliphatic hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having ≥1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepared These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to solution of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temperature for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC50 of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT